← All trials
NCT05314569
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 15, 2022
- Primary completion
- Sep 20, 2022
- Completion date
- Sep 25, 2022
- First posted
- Apr 6, 2022
- Last posted
- Jul 20, 2022
- Enrollment
- 81
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cairo UniversityLead sponsor
- Cairo UniversityOverall official - principal investigator
- Cairo UniversityReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.